A Phase 1B, Open-Label, Dose-Escalation Study of the Safety of and Antigen-specific Immune Responses Elicited by VB10.NEO in Combination With Atezolizumab in Patients With Locally Advanced and Metastatic Tumors
Latest Information Update: 06 May 2024
At a glance
- Drugs Atezolizumab (Primary) ; VB10-NEO (Primary)
- Indications Anal cancer; Cervical cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Nykode Therapeutics
- 26 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 27 Jan 2023 Planned number of patients changed from 40 to 60.
- 27 Aug 2021 New trial record